CDK4

CDK4
Pleiotrope · Public domain · source
Name	Cyclin-dependent kinase 4
Uniprot	P11802
Organism	Homo sapiens

CDK4 Cyclin-dependent kinase 4 is a serine/threonine kinase involved in cell cycle control. It functions with cyclins to phosphorylate substrates and integrate signals from growth factors, oncogenes, and tumor suppressors. CDK4 activity is implicated in development, tissue homeostasis, oncogenesis, and responses to targeted therapies.

Function and Mechanism

CDK4 associates with D-type cyclins to form an active kinase complex that phosphorylates retinoblastoma family proteins, driving G1 to S phase progression. Cellular signaling pathways such as those mediated by Epidermal growth factor receptor, Insulin-like growth factor 1 receptor, PDGF receptor, RAS, PI3K, AKT, and MAPK/ERK pathway modulate CDK4 activation, while tumor suppressors including RB, TP53, CDKN2A, and FBXW7 influence its inhibition and turnover. CDK4 phosphorylates the retinoblastoma protein and related pocket proteins, releasing E2F transcription factors like E2F1 and promoting expression of S-phase genes such as those regulated by MYC and E2F4.

Structure and Regulation

The kinase domain of CDK4 adopts a bilobed fold common to the protein kinase family and requires binding to cyclin D isoforms for full activation. Structural determinants include the ATP-binding site, activation loop, and cyclin-interaction interface, similar to kinases studied in X-ray crystallography efforts led by institutions like European Molecular Biology Laboratory and Cold Spring Harbor Laboratory. CDK4 is regulated by phosphorylation events mediated by kinases and phosphatases associated with CDC25A, WEE1, and PP2A complexes, and by cyclin-dependent kinase inhibitors encoded by CDKN2A (p16^INK4a), CDKN1A (p21), and CDKN1B (p27). Proteostasis of CDK4 involves ubiquitin ligases such as MDM2 and the proteasome pathway emphasized in work from Howard Hughes Medical Institute researchers.

Role in Cell Cycle and Development

In multicellular organisms CDK4-cyclin D activity coordinates mitogenic signals with cell cycle entry during development in tissues like the brain, heart, liver, and hematopoietic system. Mouse models generated by laboratories at National Institutes of Health and Jackson Laboratory have demonstrated roles for CDK4 in organogenesis and stem cell maintenance, with interactions involving developmental regulators such as Notch signaling, Wnt signaling, and transcription factors like SOX2 and OCT4. Dysregulated CDK4 activity perturbs checkpoints conserved from yeast models including Saccharomyces cerevisiae and Schizosaccharomyces pombe, informing comparative studies by groups at University of Cambridge and Massachusetts Institute of Technology.

Clinical Significance and Disease Associations

Aberrant CDK4 activity is linked to multiple cancers including melanoma, breast cancer, non-small cell lung cancer, glioblastoma, glioma, sarcoma, and pancreatic cancer. Genetic alterations such as amplification, mutation, and loss of regulators (for example deletions in CDKN2A or amplification of CCND1) are observed in cohorts analyzed by consortia like The Cancer Genome Atlas and International Cancer Genome Consortium. Germline mutations in CDK4 have been associated with hereditary melanoma pedigrees studied by centers including MD Anderson Cancer Center and Dana-Farber Cancer Institute. Beyond oncology, CDK4 influences metabolic regulation, with implications for conditions studied at World Health Organization and American Diabetes Association forums.

Therapeutic Targeting and Inhibitors

Selective inhibition of CDK4/6 has produced clinically approved agents and ongoing trials led by pharmaceutical companies and academic centers. Small-molecule inhibitors developed and tested in trials by groups at AstraZeneca, Pfizer, Novartis, and Eli Lilly and Company include compounds targeting the ATP-binding pocket and allosteric sites. Combination strategies integrate CDK4/6 inhibitors with therapies directed at HER2, PI3K, mTOR, immune checkpoint inhibitors such as pembrolizumab and nivolumab, and endocrine agents used in breast cancer management. Resistance mechanisms involving amplification of CDK6, activation of Cyclin E1 (CCNE1), or alterations in RB are under investigation in translational programs at Memorial Sloan Kettering Cancer Center, University of California, San Francisco, and Stanford University. Ongoing research into biomarkers for response and toxicity is conducted in collaboration with agencies such as the Food and Drug Administration and European Medicines Agency.

Category:Cell cycle proteins